Angioblast phenotypes in ECSCR loss of function
Injection . | Phenotype, % of observed . | |||
---|---|---|---|---|
Normal . | Mild . | Severe . | Toxic . | |
cMO 14 ng (36) | 83 | 6 | 0 | 11 |
MO1 10 ng (20)* | 31 | 54 | 0 | 15 |
MO2 10 ng (18)* | 22 | 61 | 17 | 0 |
MO2 14 ng (17) | 29 | 24 | 24 | 24 |
MO2 10 ng + hECSCR mRNA (37)† | 62 | 30 | 0 | 8 |
Injection . | Phenotype, % of observed . | |||
---|---|---|---|---|
Normal . | Mild . | Severe . | Toxic . | |
cMO 14 ng (36) | 83 | 6 | 0 | 11 |
MO1 10 ng (20)* | 31 | 54 | 0 | 15 |
MO2 10 ng (18)* | 22 | 61 | 17 | 0 |
MO2 14 ng (17) | 29 | 24 | 24 | 24 |
MO2 10 ng + hECSCR mRNA (37)† | 62 | 30 | 0 | 8 |
Zebrafish were injected with morpholinos as indicated, and scored at 14 som for etsrp+ angioblast positioning. Numbers in parentheses indicate the total number scored, and the incidence of each possible phenotype is given as a percentage of all scored embryos. Criteria: Embryos were scored as normal if there was evidence of a nascent midline vascular cord; mildly affected if midline angioblasts were sparse or absent; severely affected if individual angioblasts appeared lateral to the main row (ie, wrong direction); and toxic if the entire embryo appeared to be adversely affected.
ECSCR indicates endothelial-cell specific chemotaxis receptor.
Significant differences of observed distributions are indicated as follows: *P < .001 versus cMO injected;
P < .001 versus MO2 10 ng injected, using χ2 test excluding embryos scored as toxic.